These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

579 related items for PubMed ID: 17256746

  • 1. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
    Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ.
    Hepatology; 2007 Feb; 45(2):307-13. PubMed ID: 17256746
    [Abstract] [Full Text] [Related]

  • 2. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG, Giouleme O, Koumerkeridis G, Koumaras H, Tziomalos K, Patsiaoura K, Grammatikos N, Mpoumponaris A, Gkisakis D, Theodoropoulos K, Panderi A, Katsinelos P, Eugenidis N.
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [Abstract] [Full Text] [Related]

  • 3. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, Mecenate F, Paffetti A, Barlattani A, Struglia C, Villani R, Nauri L, Nosotti L, Armignacco O, Ferri F, Camporiondo MP, Soccorsi F, Club Epatologi Ospedalieri (CLEO) Group.
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS.
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [Abstract] [Full Text] [Related]

  • 5. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
    Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, Bonovas S, Esteban R.
    J Hepatol; 2007 Sep; 47(3):366-72. PubMed ID: 17561304
    [Abstract] [Full Text] [Related]

  • 6. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI.
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [Abstract] [Full Text] [Related]

  • 7. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S, Doss W, El Din SS, Hassan K, Zeid AA.
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [Abstract] [Full Text] [Related]

  • 8. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
    Idilman R, Kaymakoglu S, Oguz Onder F, Ahishali E, Bektas M, Cinar K, Pinarbasi B, Karayalcin S, Badur S, Cakaloglu Y, Mithat Bozdayi A, Bozkaya H, Okten A, Yurdaydin C.
    J Viral Hepat; 2009 Apr; 16(4):279-85. PubMed ID: 19222742
    [Abstract] [Full Text] [Related]

  • 9. [A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B].
    Zhao H, Zhang YX, Chen XY, Wang L, Tang XP, Si CW.
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):294-7. PubMed ID: 17637268
    [Abstract] [Full Text] [Related]

  • 10. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
    Wang JC, He LL, Chen Q.
    Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1162-6. PubMed ID: 23690184
    [Abstract] [Full Text] [Related]

  • 11. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH, Xie YJ, Zhao NF, Pan HY, Li MW, Huang HJ.
    World J Gastroenterol; 2015 Mar 07; 21(9):2746-53. PubMed ID: 25759545
    [Abstract] [Full Text] [Related]

  • 12. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY, Chuang WL, Hsieh MY, Lee LP, Huang JF, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, Chang WY, Yu ML.
    Antiviral Res; 2007 Aug 07; 75(2):146-51. PubMed ID: 17400303
    [Abstract] [Full Text] [Related]

  • 13. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
    Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW.
    Gut; 2011 Feb 07; 60(2):247-54. PubMed ID: 21036792
    [Abstract] [Full Text] [Related]

  • 14. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis.
    Liaw YF, Lee CM, Chien RN, Yeh CT.
    J Viral Hepat; 2006 Apr 07; 13(4):250-5. PubMed ID: 16611191
    [Abstract] [Full Text] [Related]

  • 15. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W, Yuan H, Mao XR, Deng YD, Chen L.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar 07; 21(3):184-8. PubMed ID: 23967738
    [Abstract] [Full Text] [Related]

  • 16. Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy.
    Wang LC, Chen EQ, Cao J, Liu L, Wang JR, Lei BJ, Tang H.
    J Viral Hepat; 2010 Mar 07; 17(3):178-84. PubMed ID: 19656287
    [Abstract] [Full Text] [Related]

  • 17. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH, Cho M, Yoon KT, Bae JH, Heo J, Kim GH, Kang DH, Song GA.
    Korean J Hepatol; 2008 Dec 07; 14(4):503-12. PubMed ID: 19119245
    [Abstract] [Full Text] [Related]

  • 18. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
    Xing J, Han T, Liu L, Li Y, Li J, Li Y, Xiao SX.
    Zhonghua Gan Zang Bing Za Zhi; 2011 Nov 07; 19(11):828-32. PubMed ID: 22433304
    [Abstract] [Full Text] [Related]

  • 19. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
    Manolakopoulos S, Bethanis S, Koutsounas S, Goulis J, Vlachogiannakos J, Christias E, Saveriadis A, Pavlidis C, Triantos C, Christidou A, Papatheodoridis G, Karamanolis D, Tzourmakliotis D.
    Aliment Pharmacol Ther; 2008 Feb 01; 27(3):266-73. PubMed ID: 17988233
    [Abstract] [Full Text] [Related]

  • 20. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM.
    Antivir Ther; 2012 Feb 01; 17(4):701-9. PubMed ID: 22358132
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.